Commercializing Living Therapies with CCRM CCRM

Featuring:

Jacki Jenuth, PhD, Partner and COO, Lumira Ventures

Robin Quirk, PhD MBA, Vice President, Technology Sourcing and Venture Development, CCRM

***

In this episode, we explore the dynamics of venture capital (VC) and company creation with Jacki Jenuth, Partner and COO, Lumira Ventures, and Robin Quirk, Vice President, Technology Sourcing and Venture Development, CCRM. The conversation covers the essence of venture capital funding, from how VCs evaluate investment potential to crucial considerations for founders who are attracting investment during product development. 

We also discuss red flags and common pitfalls for founders seeking funding along with the current enthusiasm among VCs for investing in cell and gene therapies. Our guests explain the strategy of bundling technologies to create stronger companies. 

The episode concludes with a glimpse into exciting projects and investments in the cell and gene therapy space, highlighting the ongoing innovation and opportunities in this field. 

Thanks for listening to Commercializing Living Therapies with CCRM. Spread the word about this episode by taking a screen cap on your device and posting it to social media using the hashtag #CCRMpodcast. Please leave us a review on your favourite streaming service. Find more episodes at ccrm.ca/podcast.

Featuring:

Michael Rosu-Myles, PhD, Executive Director, Health Canada

Josephine Lembong, PhD, Senior Manager, Science and Industry Affairs, Alliance for Regenerative Medicine
***

Currently, there are more than 2,000 cell and gene therapies in clinical trials worldwide. With a goal of ensuring that safe and quality products are approved for use by patients, regulators determine whether these innovative therapies move from the lab to market.

In this interview, Michael Rosu-Myles, PhD, Executive Director, Health Canada, and Josephine Lembong, PhD, Senior Manager, Science and Industry Affairs, Alliance for Regenerative Medicine, provide listeners with an exclusive look at how regulators are preparing for an increased number of applications for cell and gene therapy products in the years to come. 

Our guests discuss how Health Canada, the U.S. Food and Drug Administration and European Medicines Agency have created new regulatory frameworks and offices to enhance their ability to review cell and gene therapy submissions. Listeners will learn how companies that are planning a submission can prepare to work successfully with regulators, whether regulators consider the potential price tags of these therapies, and how patients benefit from regulators’ work. 

Thanks for listening to Commercializing Living Therapies with CCRM. Spread the word about this episode by taking a screen cap on your device and posting it to social media using the hashtag #CCRMpodcast. Please leave us a review on your favourite streaming service. Find more episodes at ccrm.ca/podcast.

Featuring:
Sonia Sennik, Executive Director, Creative Destruction Lab

Glenn MacLean, Director, Technology Sourcing and Venture Development, CCRM

***
In many science-oriented fields, including regenerative medicine and advanced therapies, researchers and company founders often require additional support and expertise to successfully commercialize their discoveries. 

With a mission of enhancing the commercialization of science for the betterment of humankind, Creative Destruction Lab is a valuable resource for start-up founders to  help de-risk their business and maximize their probability of success. Its Advanced Therapies stream supports founders solving biological, medical and healthcare problems using innovative applications of cell and gene therapies, and other biological products. 

In this interview, Sonia Sennik, Executive Director, Creative Destruction Lab, and Glenn MacLean, Director, Technology Sourcing and Venture Development, CCRM, discuss how Creative Destruction Lab’s processes and mentors can help drive a discovery to the market. Our guests explain the practical steps and tactics, and also discuss the program’s potential future impact on Canada’s regenerative medicine and advanced therapies sector.

Thanks for listening to Commercializing Living Therapies with CCRM. Spread the word about this episode by taking a screen cap on your device and posting it to social media using the hashtag #CCRMpodcast. Please leave us a review on your favourite streaming service. Find more episodes at ccrm.ca/podcast.

Featuring:
Matthew Durdy, Chief Executive Officer, Cell and Gene Therapy Catapult

Michael May, PhD, President and Chief Executive Officer, CCRM

***
Public-private partnerships are collaborations between government agencies and private-sector companies. In this interview, Matthew Durdy, CEO, Cell and Gene Therapy Catapult, and Michael May, President and CEO, CCRM, explain how these collaborations have had an impact in the regenerative medicine sector by advancing cell and gene therapies along the commercialization pathway. Our guests share highlights from their organizations, including the types of partners they have worked with, and the infrastructure and facilities they have helped to create. 


The interview concludes with a discussion of how public-private partnerships will benefit patients in the future by improving the factors that lead to market access and adoption, such as developing markets, promoting acceptability, reducing the cost of goods, and enabling the supply chain.

Thanks for listening to Commercializing Living Therapies with CCRM. Spread the word about this episode by taking a screen cap on your device and posting it to social media using the hashtag #CCRMpodcast. Please leave us a review on your favourite streaming service. Find more episodes at ccrm.ca/podcast.

Featuring:
Matthew Miller, B.M.Sc., PhD, Director, Michael G. DeGroote Institute for Infectious Disease Research; Co-Director, Canadian Pandemic Preparedness Hub (CP2H), McMaster University 
Patrycja Thompson, PhD, Director, Strategy & Operations, the Canadian Hub for Health Intelligence & Innovation in Infectious Diseases (HI3), University of Toronto
***
The COVID-19 pandemic illuminated a need to scale up Canada’s biomanufacturing capacity. As a response, the Government of Canada established new research and innovation hubs at five Canadian universities. These hubs aim to combine the strengths of academia, industry, and the public and not-for-profit sectors to jointly improve pandemic readiness and enhance the nation’s biomanufacturing and life sciences[SJ1] .
In this episode, we explore two of the five hubs. Matthew Miller, B.M.Sc., PhD, speaks to the Canadian Pandemic Preparedness Hub, led by the University of Ottawa and McMaster University, while Patrycja Thompson, PhD, covers the Canadian Hub for Health Intelligence & Innovation in Infectious Diseases, led by the University of Toronto. 
As our guests discuss how these multidisciplinary research hubs are accelerating the research and development of next-generation vaccines and therapeutics, including cell and gene therapies, listeners will also learn how they support training and development to expand the pipeline of skilled talent. Plus, hear what our guests are excited about as they look to the future of the hubs program and the field as a whole.

Thanks for listening to Commercializing Living Therapies with CCRM. Spread the word about this episode by taking a screen cap on your device and posting it to social media using the hashtag #CCRMpodcast. Please leave us a review on your favourite streaming service. Find more episodes at ccrm.ca/podcast.

Featuring:


Mamatha Bhat MD, MSc, PhD, FRCPC
Hepatologist & Co-Lead of Transplant AI initiative (TAI), Ajmera Transplant Program Scientist, Toronto General Hospital Research Institute, University Health Network
Associate Professor, Division of Gastroenterology & Hepatology
Director, Clinician-Scientist Training Program (CSTP), Department of Medicine, University of Toronto
Partnerships & Engagement Lead, Temerty Centre for AI in Research & Education in Medicine (T-CAIREM); Faculty Affiliate, Vector

Julie Audet, PhD, PEng, Professor Biomedical Engineering, University of Toronto
 
*** 


Although artificial intelligence (AI) is a hot topic right now, many professionals working in the regenerative medicine field may not be aware of how it is already being used to support cell and gene therapies. In this episode, Mamatha Bhat MD, PhD, FRCPC, and Julie Audet, PhD, PEng, discuss the ways that AI is being used in the life sciences and health care field, as well as in their work. Additionally, our guests highlight some positive and promising research findings that reveal how AI can be used in the regenerative medicine field, and how AI can support the manufacturing of cell and gene therapies. And addressing the concern we all have, our guests consider the possible impacts of AI on jobs in the regenerative medicine field, as well as the potential effects of AI on living therapies more broadly. 



Thanks for listening to Commercializing Living Therapies with CCRM. Spread the word about this episode by taking a screen cap on your device and posting it to social media using the hashtag #CCRMpodcast. Please leave us a review on your favourite streaming service. Find more episodes at ccrm.ca/podcast.